2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-111018
    FPL 62129 95445-79-7 98%
    FPL 62129 is an antagonist for calcium channel. FPL 62129 reduces blood pressure and total peripheral resistance, increases the cardiac contractility and cardiac output in anarsthetised beagle model. FPL 62129 also serves as a vasodilator and a direct decelerator.
    FPL 62129
  • HY-111084
    UK 52831 93118-77-5 98%
    UK 52831 is a long acting dihydropyridine calcium channel antagonist. UK 52831 can be used for cardiovascular disease (such as hypertension and myocardial ischemia) and anti-inflammatory research.
    UK 52831
  • HY-111239
    GSK317354A 874119-13-8 98%
    GSK317354A is a ROCK and GRK inhibitor. GSK317354A can be used for heart failure and Parkinson’s disease research.
    GSK317354A
  • HY-111245
    AZD-1305 872045-91-5 98%
    AZD-1305 is an antiarrhythmic agent and atrial selective sodium channel/potassium channel blocker, which can significantly prolongs action potential duration and reduces excitability, cause atrial selective ERP prolongation and acute termination of atrial fibrillation. AZD1305 can be used for atrial fibrillation research.
    AZD-1305
  • HY-111247
    Ro 09-0680 87112-49-0 98%
    Ro 09-0680 is a potent inhibitor of rabbit platelet aggregation induced by Collagen with an IC50 of 6.6 μM.
    Ro 09-0680
  • HY-111259
    Ro 31-1118 free base 81228-35-5 98%
    Ro 31-1118 Free base is a compound exhibiting weak antihypertensive activity in patients with mild hypertension. Ro 31-1118 Free base demonstrated a reduction in heart rates and blood pressure post-exercise at varying doses. Ro 31-1118 Free base exhibited linear pharmacokinetics within the 10-80 mg dose range. Ro 31-1118 Free base showed no significant impact on diastolic blood pressure or adverse effects during the study.
    Ro 31-1118 free base
  • HY-111326
    Naphazoline 835-31-4 99.74%
    Naphazoline (Naphthazoline) is a potent α-adrenergic receptor agonist. Naphazoline reduces vascular hyperpermeability and promotes vasoconstriction. Naphazoline reduces the levels of inflammatory factors (TNF-α, IL-1β and IL-6), cytokines (IFN-γ and IL-4), IgE, GMCSF, and NGF. Naphazoline can be used for non-bacterial conjunctivitis research.
    Naphazoline
  • HY-111348
    Lamifiban 144412-49-7 98%
    Lamifiban is a nonpeptide glycoprotein IIb/IIIa receptor and platelet aggregation antagonist. Lamifiban in combination with thrombolytic therapy effectively restores coronary arterial patency. Lamifiban is promising for research of acute coronary syndromes.
    Lamifiban
  • HY-111766
    YD-3 170632-41-4 98%
    YD-3 is a platelet activation inhibitor. YD-3 inhibits Thrombine-induced rabbit platelets aggregation (IC50: 28.3 μM) and phosphoinositol production. In addition, YD-3 also inhibits Trypsin-induced platelet aggregation in human and rabbit with the IC50 of 38.1 μM and 5.7 μM, respectively, but does not affect the proteolytic activity of trypsin.
    YD-3
  • HY-111990
    Tetrofosmin 127502-06-1 98%
    Tetrofosmin is a drug used in nuclear medicine cardiac imaging.
    Tetrofosmin
  • HY-112074
    Tiamenidine 31428-61-2 98%
    Tiamenidine (HOE 440) is an orally active α2-adrenergic receptor agonist with antihypertensive effect. Tiamenidine is used as an antihypertensive agent for hypertension research.
    Tiamenidine
  • HY-112160
    XL-784 free base 1356992-21-6 98%
    XL-784 free base is a selective matrix metalloproteinases (MMP) inhibitor, with IC50s of ~1900, 0.81, 120, 10.8, 18, 0.56 nM for MMP-1, MMP-2, MMP-3, MMP-8, MMP-9 and MMP-13, respectively.
    XL-784 free base
  • HY-112264
    ETA antagonist 1 161801-60-1 98%
    ETA antagonist 1 is a ETA selective antagonist with an IC50 of 0.08 μM.
    ETA antagonist 1
  • HY-112290
    MK-0736 719272-79-4 98%
    MK-0736 is a 11β-HSD type 1 (11β-HSD1) inhibitor that reduces blood pressure. MK-0736 can be used for type 2 diabetes and metabolic syndrome research.
    MK-0736
  • HY-112348
    HA-1004 hydrochloride 92564-34-6 98%
    HA-1004 hydrochloride is a selective inhibitor of PKA, which can inhibit lipolysis and induce vascular relaxation. HA-1004 hydrochloride is also a dual inhibitor of cyclic GMP-dependent protein kinase and cyclic AMP-dependent protein (Cyclic GMP-AMP Synthase), and is involved in smooth muscle, second messenger, cyclic AMP and cyclic GMP regulation mechanisms. HA-1004 hydrochloride an antagonist for calcium, that can be used as a vasodilator to inhibit the contraction of rabbit aortic strips, or to antagonize ERK and tyrosine hydroxylase (TH) phosphorylation in morphine abstinence rat models.
    HA-1004 hydrochloride
  • HY-112417
    Ki11502 347155-76-4 99.30%
    Ki11502 is a multi-targeted receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the activity of PDGF β/α receptors with IC50 values less than 10 nM. Ki11502 selectively inhibits PDGF β receptor phosphorylation, proliferation, and proteoglycan synthesis in human vascular smooth muscle cells. Ki11502 can induce Apoptosis) and exhibits profound antiproliferative effects on select subsets of leukemia, including those with Imatinib (HY-15463) resistant mutations. Ki11502 is highly suitable for studying the role of PDGF in vascular diseases, particularly the role of proteoglycans in atherosclerosis.
    Ki11502
  • HY-112549
    5-oxo-ETE 106154-18-1 98%
    5-oxo-ETE is a potent chemoattractant for eosinophils. 5-oxo-ETE inhibits selenium-induced apoptosis in prostate cancer cells. 5-oxo-ETE can be used in research into asthma, allergic diseases, cancer and cardiovascular disease.
    5-oxo-ETE
  • HY-112575
    Tiazotic acid 64679-65-8 98%
    Tiazotic acid is a metabolic agent that has immunomodulatory, anti-inflammatory, antioxidant, anti-ischemic, cardio- and endothelioprotective, antiplatelet, hepatoprotective activities. Tiazotic acid increases the levels of eNOS. Tiazotic acid also reduces the level of D-dimer in the blood, which reduces the risks of heart attacks and strokes in post-COVID syndrome.
    Tiazotic acid
  • HY-112968
    Human protein C 925910-74-3 98%
    Human Protein C is activated by α-thrombin or α-thrombin/thrombomodulin complex to a serine protease, namely activated protein C (APC). Human Protein C can selectively inactivate factors Va and VIIIa and is a potent anticoagulant.
    Human protein C
  • HY-113000
    Cetoleic acid 1002-96-6 98%
    Cetoleic acid is a long-chain monounsaturated fatty acid found in deep-sea fish. Cetoleic acid can promote the synthesis of ALA in human HepG2 cells and EPA in vitro in salmon liver cells, affecting cholesterol levels in rodents. Cetoleic acid has potential applications in cardiovascular disease research.
    Cetoleic acid
Cat. No. Product Name / Synonyms Application Reactivity